Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Preudhomme C, et al. Among authors: jourdan e. N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095. N Engl J Med. 2010. PMID: 21175313 Free article. Clinical Trial.
One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
Jourdan E, Rigal-Huguet F, Marit G, Vey N, Dastugue N, Fegueux N, Molina L, Gastaut JA, Legros L, Zerazhi H, Cailleres S, Bauduer F, Bordessoule D, Attal M, Blaise D, Pigneux A; BGMT Study Group. Jourdan E, et al. Br J Haematol. 2005 May;129(3):403-10. doi: 10.1111/j.1365-2141.2005.05470.x. Br J Haematol. 2005. PMID: 15842665 Free article. Clinical Trial.
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience.
Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F, Molina L, Fegueux N, Pigneux A, Recher C, Rossi JF, Attal M, Sotto JJ, Maraninchi D, Reiffers J, Bardou VJ, Esterni B, Blaise D. Jourdan E, et al. J Clin Oncol. 2005 Oct 20;23(30):7676-84. doi: 10.1200/JCO.2005.02.5940. Epub 2005 Sep 26. J Clin Oncol. 2005. PMID: 16186596 Clinical Trial.
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
Pigneux A, Harousseau JL, Witz F, Sauvezie M, Bene MC, Luquet I, Hunault-Berger M, Recher C, Lioure B, Himberlin C, Escoffre-Barbe M, Berthou C, Lissandre S, Fegueux N, Cahn JY, Jourdan E, Dreyfus F, Reiffers J, Milpied N, Ifrah N. Pigneux A, et al. Among authors: jourdan e. J Clin Oncol. 2010 Jun 20;28(18):3028-34. doi: 10.1200/JCO.2009.26.4648. Epub 2010 May 17. J Clin Oncol. 2010. PMID: 20479424
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terré C, Guardiola P, Béné MC, Preudhomme C, Ifrah N, Dombret H; French AML Intergroup. Jourdan E, et al. Blood. 2013 Mar 21;121(12):2213-23. doi: 10.1182/blood-2012-10-462879. Epub 2013 Jan 15. Blood. 2013. PMID: 23321257 Free article. Clinical Trial.
Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
Duployez N, Nibourel O, Marceau-Renaut A, Willekens C, Helevaut N, Caillault A, Villenet C, Celli-Lebras K, Boissel N, Jourdan E, Dombret H, Figeac M, Preudhomme C, Renneville A. Duployez N, et al. Among authors: jourdan e. Am J Hematol. 2014 Jun;89(6):610-5. doi: 10.1002/ajh.23696. Epub 2014 Mar 8. Am J Hematol. 2014. PMID: 24616160 Free article. Clinical Trial.
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.
Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, Lacombe C, Lapillonne H, Etancelin P, Figeac M, Renneville A, Castaigne S, Leverger G, Ifrah N, Dombret H, Preudhomme C, Abdel-Wahab O, Jourdan E. Micol JB, et al. Among authors: jourdan e. Blood. 2014 Aug 28;124(9):1445-9. doi: 10.1182/blood-2014-04-571018. Epub 2014 Jun 27. Blood. 2014. PMID: 24973361 Free PMC article. Clinical Trial.
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM). Thepot S, et al. Among authors: jourdan e. Leuk Res. 2014 Dec;38(12):1430-4. doi: 10.1016/j.leukres.2014.09.014. Epub 2014 Oct 7. Leuk Res. 2014. PMID: 25449687 Clinical Trial.
138 results